{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:25:27Z","timestamp":1793024727419,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson\u2019s disease dementia, affects over a million people in the USA and has a substantial impact on patients, caregivers, and society. Symptomatic treatments for LBD, which can include cognitive, neuropsychiatric, autonomic, sleep, and motor features, are limited with only two drugs (cholinesterase inhibitors) currently approved by regulatory agencies for dementia in LBD. Clinical trials represent a top research priority, but there are many challenges in the development and implementation of trials in LBD. To address these issues and advance the field of clinical trials in the LBDs, the Lewy Body Dementia Association formed an Industry Advisory Council (LBDA IAC), in addition to its Research Center of Excellence program. The LBDA IAC comprises a diverse and collaborative group of experts from academic medical centers, pharmaceutical industries, and the patient advocacy foundation. The inaugural LBDA IAC meeting, held in June 2019, aimed to bring together this group, along with representatives from regulatory agencies, to address the topic of optimizing the landscape of LBD clinical trials. This review highlights the formation of the LBDA IAC, current state of LBD clinical trials, and challenges and opportunities in the field regarding trial design, study populations, diagnostic criteria, and biomarker utilization. Current gaps include a lack of standardized clinical assessment tools and evidence-based management strategies for LBD as well as difficulty and controversy in diagnosing LBD. Challenges in LBD clinical trials include the heterogeneity of LBD pathology and symptomatology, limited understanding of the trajectory of LBD cognitive and core features, absence of LBD-specific outcome measures, and lack of established standardized biologic, imaging, or genetic biomarkers that may inform study design. Demands of study participation (e.g., travel, duration, and frequency of study visits) may also pose challenges and impact trial enrollment, retention, and outcomes. There are opportunities to improve the landscape of LBD clinical trials by harmonizing clinical assessments and biomarkers across cohorts and research studies, developing and validating outcome measures in LBD, engaging the patient community to assess research needs and priorities, and incorporating biomarker and genotype profiling in study design.<\/jats:p>","DOI":"10.1186\/s13195-020-00703-5","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T21:02:43Z","timestamp":1604005363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5014-7535","authenticated-orcid":false,"given":"Jennifer G.","family":"Goldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah K.","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley F.","family":"Boeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanis J.","family":"Ferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Galasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kaufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Leverenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol F.","family":"Lippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Abler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Biglan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Munsie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"issue":"5","key":"703_CR1","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S1474-4422(17)30074-1","volume":"16","author":"C Mueller","year":"2017","unstructured":"Mueller C, Ballard C, Corbett A, Aarsland D. The prognosis of dementia with Lewy bodies. Lancet Neurol. 2017;16(5):390\u20138.","journal-title":"Lancet Neurol"},{"issue":"4","key":"703_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1017\/S0033291713000494","volume":"44","author":"SA Vann Jones","year":"2014","unstructured":"Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44(4):673\u201383.","journal-title":"Psychol Med"},{"issue":"23","key":"703_CR3","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1212\/WNL.0000000000004717","volume":"89","author":"RA Corriveau","year":"2017","unstructured":"Corriveau RA, Koroshetz WJ, Gladman JT, Jeon S, Babcock D, Bennett DA, et al. Alzheimer\u2019s Disease-Related Dementias Summit 2016: national research priorities. Neurology. 2017;89(23):2381\u201391.","journal-title":"Neurology."},{"issue":"11","key":"703_CR4","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/mds.26352","volume":"30","author":"JG Goldman","year":"2015","unstructured":"Goldman JG, Weintraub D. Advances in the treatment of cognitive impairment in Parkinson\u2019s disease. Mov Disord. 2015;30(11):1471\u201389.","journal-title":"Mov Disord"},{"issue":"11","key":"703_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/13543784.2019.1681398","volume":"28","author":"G Lee","year":"2019","unstructured":"Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN. Clinical drug development for dementia with Lewy bodies: past and present. Expert Opin Investig Drugs. 2019;28(11):951\u201365.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"703_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13195-019-0476-1","volume":"11","author":"B Peterson","year":"2019","unstructured":"Peterson B, Armstrong M, Galasko D, Galvin JE, Goldman J, Irwin D, et al. Lewy Body Dementia Association\u2019s Research Centers of Excellence Program: inaugural meeting proceedings. Alzheimers Res Ther. 2019;11(1):23.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"703_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13023-020-01387-8","volume":"15","author":"I Peterson","year":"2020","unstructured":"Peterson I, Cruz R, Sarr F, Stanley AM, Jarecki J. The SMA Clinical Trial Readiness Program: creation and evaluation of a program to enhance SMA trial readiness in the United States. Orphanet J Rare Dis. 2020;15(1):118.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"703_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/resp.12458","volume":"20","author":"DM Rose","year":"2015","unstructured":"Rose DM, Marshall R, Surber MW. Pharmaceutical industry, academia and patient advocacy organizations: what is the recipe for synergic (win-win-win) collaborations? Respirology. 2015;20(2):185\u201391.","journal-title":"Respirology."},{"key":"703_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.trci.2018.04.008","volume":"4","author":"J Cummings","year":"2018","unstructured":"Cummings J, Reiber C, Kumar P. The price of progress: funding and financing Alzheimer\u2019s disease drug development. Alzheimers Dement (N Y). 2018;4:330\u201343.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"12","key":"703_CR10","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/gps.4609","volume":"32","author":"AJ Thomas","year":"2017","unstructured":"Thomas AJ, Taylor JP, McKeith I, Bamford C, Burn D, Allan L, et al. Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. Int J Geriatr Psychiatry. 2017;32(12):1280\u2013304.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"703_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.parkreldis.2010.03.007","volume":"16","author":"JE Galvin","year":"2010","unstructured":"Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit SH. Lewy body dementia: the caregiver experience of clinical care. Parkinsonism Relat Disord. 2010;16(6):388\u201392.","journal-title":"Parkinsonism Relat Disord"},{"issue":"16","key":"703_CR12","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1002\/mds.23391","volume":"25","author":"K Dujardin","year":"2010","unstructured":"Dujardin K, Dubois B, Tison F, Durif F, Bourdeix I, Pere JJ, et al. Parkinson\u2019s disease dementia can be easily detected in routine clinical practice. Mov Disord. 2010;25(16):2769\u201376.","journal-title":"Mov Disord"},{"issue":"1","key":"703_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology."},{"issue":"12","key":"703_CR14","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord. 2007;22(12):1689\u2013707 quiz 837.","journal-title":"Mov Disord"},{"key":"703_CR15","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"3","key":"703_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349\u201356.","journal-title":"Mov Disord"},{"issue":"17","key":"703_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743\u201355.","journal-title":"Neurology."},{"issue":"3","key":"703_CR18","first-page":"316","volume":"1","author":"JE Galvin","year":"2015","unstructured":"Galvin JE. Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score. Alzheimers Dement Diagn Assess Dis Monit. 2015;1(3):316\u201324.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"703_CR19","unstructured":"LBDA. Comprehensive LBD symptoms checklist. Available from: www.lbda.org ."},{"issue":"4","key":"703_CR20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/WAD.0000000000000279","volume":"32","author":"L Besser","year":"2018","unstructured":"Besser L, Kukull W, Knopman DS, Chui H, Galasko D, Weintraub S, et al. Version 3 of the National Alzheimer\u2019s Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord. 2018;32(4):351\u20138.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"10","key":"703_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/gps.4948","volume":"33","author":"AJ Thomas","year":"2018","unstructured":"Thomas AJ, Taylor JP, McKeith I, Bamford C, Burn D, Allan L, et al. Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: the DIAMOND Lewy study. Int J Geriatr Psychiatry. 2018;33(10):1293\u2013304.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"2","key":"703_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","volume":"19","author":"J-P Taylor","year":"2020","unstructured":"Taylor J-P, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157\u201369.","journal-title":"Lancet Neurol"},{"key":"703_CR23","first-page":"189","volume":"17","author":"M Verny","year":"2019","unstructured":"Verny M, Blanc F. Lewy body dementia: therapeutic propositions according to evidence based medicine and practice. Geriatr Psychol Neuropsychiatr Vieill. 2019;17:189\u201397.","journal-title":"Geriatr Psychol Neuropsychiatr Vieill"},{"issue":"8","key":"703_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","volume":"172","author":"C Stinton","year":"2015","unstructured":"Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(8):731\u201342.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"703_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40266-018-00636-7","volume":"36","author":"LA Hershey","year":"2019","unstructured":"Hershey LA, Coleman-Jackson R. Pharmacological management of dementia with Lewy bodies. Drugs Aging. 2019;36(4):309\u201319.","journal-title":"Drugs Aging"},{"issue":"2","key":"703_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence-based medicine review. Mov Disord. 2019;34(2):180\u201398.","journal-title":"Mov Disord"},{"issue":"9","key":"703_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11910-017-0778-2","volume":"17","author":"L Velayudhan","year":"2017","unstructured":"Velayudhan L, Ffytche D, Ballard C, Aarsland D. New therapeutic strategies for Lewy body dementias. Curr Neurol Neurosci Rep. 2017;17(9):68.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"10","key":"703_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"9","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969\u201377.","journal-title":"Lancet Neurol"},{"issue":"12","key":"703_CR29","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863\u201372.","journal-title":"Neurology."},{"issue":"Pt 8","key":"703_CR30","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1093\/brain\/aws173","volume":"135","author":"J Graff-Radford","year":"2012","unstructured":"Graff-Radford J, Boeve BF, Pedraza O, Ferman TJ, Przybelski S, Lesnick TG, et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain. 2012;135(Pt 8):2470\u20137.","journal-title":"Brain."},{"issue":"7","key":"703_CR31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/mds.26236","volume":"30","author":"E Mamikonyan","year":"2015","unstructured":"Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord. 2015;30(7):912\u20138.","journal-title":"Mov Disord"},{"issue":"5","key":"703_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/mds.26617","volume":"31","author":"D Weintraub","year":"2016","unstructured":"Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A, et al. Rasagiline for mild cognitive impairment in Parkinson\u2019s disease: a placebo-controlled trial. Mov Disord. 2016;31(5):709\u201314.","journal-title":"Mov Disord"},{"issue":"3","key":"703_CR33","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/mdc3.12455","volume":"4","author":"VK Hinson","year":"2017","unstructured":"Hinson VK, Delambo A, Elm J, Turner T. A randomized clinical trial of atomoxetine for mild cognitive impairment in Parkinson\u2019s disease. Mov Disord Clin Pract. 2017;4(3):416\u201323.","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"703_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ana.23557","volume":"72","author":"E Mori","year":"2012","unstructured":"Mori E, Ikeda M, Kosaka K, Donepezil DLBSI. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41\u201352.","journal-title":"Ann Neurol"},{"issue":"24","key":"703_CR35","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2509\u201318.","journal-title":"N Engl J Med"},{"issue":"7","key":"703_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","volume":"8","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613\u20138.","journal-title":"Lancet Neurol"},{"issue":"10","key":"703_CR37","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/mds.25098","volume":"27","author":"B Dubois","year":"2012","unstructured":"Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, et al. Donepezil in Parkinson\u2019s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27(10):1230\u20138.","journal-title":"Mov Disord"},{"issue":"4","key":"703_CR38","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1377\/hlthaff.2013.1314","volume":"33","author":"JL Watson","year":"2014","unstructured":"Watson JL, Ryan L, Silverberg N, Cahan V, Bernard MA. Obstacles and opportunities in Alzheimer\u2019s clinical trial recruitment. Health Aff (Millwood). 2014;33(4):574\u20139.","journal-title":"Health Aff (Millwood)"},{"key":"703_CR39","doi-asserted-by":"publisher","first-page":"100449","DOI":"10.1016\/j.conctc.2019.100449","volume":"16","author":"S Frank","year":"2019","unstructured":"Frank S, Berk S, Hernandez L, Hogarth P, Shill HA, Siddiqi B, et al. Transportation innovation to aid Parkinson disease trial recruitment. Contemp Clin Trials Commun. 2019;16:100449.","journal-title":"Contemp Clin Trials Commun"},{"issue":"1","key":"703_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1212\/CPJ.0000000000000680","volume":"10","author":"CG Tarolli","year":"2020","unstructured":"Tarolli CG, Zimmerman GA, Goldenthal S, Feldman B, Berk S, Siddiqi B, et al. Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants. Neurol Clin Pract. 2020;10(1):7\u201314.","journal-title":"Neurol Clin Pract"},{"key":"703_CR41","unstructured":"Administration USFaD. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/alzheimers-disease-developing-drugs-treatment-guidance-industy . 2018."},{"issue":"1","key":"703_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","volume":"7","author":"M Ikeda","year":"2015","unstructured":"Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015;7(1):4.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"703_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/gps.4109","volume":"30","author":"KA Wesnes","year":"2015","unstructured":"Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson\u2019s disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2015;30(1):46\u201354.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5\u20136","key":"703_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000471507","volume":"43","author":"MI Lapid","year":"2017","unstructured":"Lapid MI, Kuntz KM, Mason SS, Aakre JA, Lundt ES, Kremers W, et al. Efficacy, safety, and tolerability of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies: a pilot study. Dement Geriatr Cogn Disord. 2017;43(5\u20136):269\u201380.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"703_CR45","doi-asserted-by":"crossref","unstructured":"Murata M, Odawara T, Hasegawa K, Kajiwara R, Takeuchi H, Tagawa M, et al. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial. Parkinsonism Relat Disord. 2020;76:91\u20137.","DOI":"10.1016\/j.parkreldis.2019.12.005"},{"issue":"8","key":"703_CR46","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1212\/WNL.0000000000005010","volume":"90","author":"M Murata","year":"2018","unstructured":"Murata M, Odawara T, Hasegawa K, Iiyama S, Nakamura M, Tagawa M, et al. Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology. 2018;90(8):e664\u2013e72.","journal-title":"Neurology."},{"issue":"10","key":"703_CR47","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1212\/01.wnl.0000184517.69816.e9","volume":"65","author":"KA Wesnes","year":"2005","unstructured":"Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology. 2005;65(10):1654\u20136.","journal-title":"Neurology."},{"issue":"2","key":"703_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/mds.27233","volume":"33","author":"M Skorvanek","year":"2018","unstructured":"Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, et al. Global scales for cognitive screening in Parkinson\u2019s disease: critique and recommendations. Mov Disord. 2018;33(2):208\u201318.","journal-title":"Mov Disord"},{"issue":"1","key":"703_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12984-020-00684-4","volume":"17","author":"N Shawen","year":"2020","unstructured":"Shawen N, O'Brien MK, Venkatesan S, Lonini L, Simuni T, Hamilton JL, et al. Role of data measurement characteristics in the accurate detection of Parkinson\u2019s disease symptoms using wearable sensors. J Neuroeng Rehabil. 2020;17(1):52.","journal-title":"J Neuroeng Rehabil"},{"issue":"5","key":"703_CR50","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/mds.27671","volume":"34","author":"AJ Espay","year":"2019","unstructured":"Espay AJ, Hausdorff JM, Sanchez-Ferro A, Klucken J, Merola A, Bonato P, et al. A roadmap for implementation of patient-centered digital outcome measures in Parkinson\u2019s disease obtained using mobile health technologies. Mov Disord. 2019;34(5):657\u201363.","journal-title":"Mov Disord"},{"issue":"10","key":"703_CR51","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/gps.2823","volume":"27","author":"DR Lee","year":"2012","unstructured":"Lee DR, Taylor JP, Thomas AJ. Assessment of cognitive fluctuation in dementia: a systematic review of the literature. Int J Geriatr Psychiatry. 2012;27(10):989\u201398.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"703_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/brain\/awz311","volume":"143","author":"E Matar","year":"2020","unstructured":"Matar E, Shine JM, Halliday GM, Lewis SJG. Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. Brain. 2020;143(1):31\u201346.","journal-title":"Brain."},{"issue":"4","key":"703_CR53","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/mds.27355","volume":"33","author":"A Siderowf","year":"2018","unstructured":"Siderowf A, Aarsland D, Mollenhauer B, Goldman JG, Ravina B. Biomarkers for cognitive impairment in Lewy body disorders: status and relevance for clinical trials. Mov Disord. 2018;33(4):528\u201336.","journal-title":"Mov Disord"},{"issue":"4","key":"703_CR54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","volume":"6","author":"I McKeith","year":"2007","unstructured":"McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6(4):305\u201313.","journal-title":"Lancet Neurol"},{"issue":"8","key":"703_CR55","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s11910-014-0472-6","volume":"14","author":"SN Gomperts","year":"2014","unstructured":"Gomperts SN. Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. Curr Neurol Neurosci Rep. 2014;14(8):472.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"11","key":"703_CR56","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","volume":"73","author":"SN Gomperts","year":"2016","unstructured":"Gomperts SN, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N, et al. Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol. 2016;73(11):1334\u201341.","journal-title":"JAMA Neurol."},{"issue":"1","key":"703_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017;16(1):55\u201365.","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"703_CR58","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/jnc.13390","volume":"139","author":"B Mollenhauer","year":"2016","unstructured":"Mollenhauer B, Parnetti L, Rektorova I, Kramberger MG, Pikkarainen M, Schulz-Schaeffer WJ, et al. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson\u2019s disease and related disorders. J Neurochem. 2016;139(Suppl 1):290\u2013317.","journal-title":"J Neurochem"},{"issue":"3","key":"703_CR59","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","volume":"3","author":"J Cummings","year":"2017","unstructured":"Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer\u2019s disease drug development pipeline: 2017. Alzheimers Dement (N Y). 2017;3(3):367\u201384.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"703_CR60","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3988\/jcn.2016.12.4.381","volume":"12","author":"D Kim","year":"2016","unstructured":"Kim D, Kim YS, Shin DW, Park CS, Kang JH. Harnessing cerebrospinal fluid biomarkers in clinical trials for treating Alzheimer\u2019s and Parkinson\u2019s diseases: potential and challenges. J Clin Neurol. 2016;12(4):381\u201392.","journal-title":"J Clin Neurol"},{"issue":"2","key":"703_CR61","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11055-009-9244-1","volume":"40","author":"IV Litvinenko","year":"2010","unstructured":"Litvinenko IV, Odinak MM, Mogil'naya VI, Perstnev SV. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson\u2019s disease complicated by dementia. Neurosci Behav Physiol. 2010;40(2):149\u201355.","journal-title":"Neurosci Behav Physiol"},{"issue":"Pt 3","key":"703_CR62","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/brain\/awm322","volume":"131","author":"L Bonanni","year":"2008","unstructured":"Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer\u2019s disease, dementia with Lewy bodies and Parkinson\u2019s disease with dementia patients with a 2-year follow-up. Brain. 2008;131(Pt 3):690\u2013705.","journal-title":"Brain."},{"key":"703_CR63","doi-asserted-by":"crossref","unstructured":"Law ZK, Todd C, Mehraram R, Schumacher J, Baker MR, LeBeau FEN, et al. The Role of EEG in the Diagnosis, Prognosis and Clinical Correlations of Dementia with Lewy Bodies-A Systematic Review. Diagnostics (Basel). 2020;10(9):E616.","DOI":"10.3390\/diagnostics10090616"},{"issue":"1","key":"703_CR64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13195-020-00650-1","volume":"12","author":"J Schumacher","year":"2020","unstructured":"Schumacher J, Taylor JP, Hamilton CA, Firbank M, Cromarty RA, Donaghy PC, et al. Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies. Alzheimers Res Ther. 2020;12(1):82.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"703_CR65","doi-asserted-by":"publisher","first-page":"e662","DOI":"10.1212\/WNL.0000000000009977","volume":"95","author":"JJ van der Zande","year":"2020","unstructured":"van der Zande JJ, Gouw AA, van Steenoven I, van de Beek M, Scheltens P, Stam CJ, et al. Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies. Neurology. 2020;95(6):e662\u2013e70.","journal-title":"Neurology."},{"key":"703_CR66","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neurobiolaging.2015.10.028","volume":"38","author":"R Guerreiro","year":"2016","unstructured":"Guerreiro R, Escott-Price V, Darwent L, Parkkinen L, Ansorge O, Hernandez DG, et al. Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson\u2019s and Alzheimer\u2019s diseases. Neurobiol Aging. 2016;38:214 e7- e10.","journal-title":"Neurobiol Aging"},{"issue":"19","key":"703_CR67","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1212\/WNL.0b013e3182735e9a","volume":"79","author":"D Tsuang","year":"2012","unstructured":"Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology. 2012;79(19):1944\u201350.","journal-title":"Neurology."},{"issue":"2","key":"703_CR68","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/jamaneurol.2013.600","volume":"70","author":"D Tsuang","year":"2013","unstructured":"Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70(2):223\u20138.","journal-title":"JAMA Neurol"},{"issue":"5","key":"703_CR69","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.27414","volume":"33","author":"SP Sardi","year":"2018","unstructured":"Sardi SP, Cedarbaum JM, Brundin P. Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic. Mov Disord. 2018;33(5):684\u201396.","journal-title":"Mov Disord"},{"issue":"1","key":"703_CR70","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12883-019-1252-3","volume":"19","author":"CRA Silveira","year":"2019","unstructured":"Silveira CRA, MacKinley J, Coleman K, Li Z, Finger E, Bartha R, et al. Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol. 2019;19(1):20.","journal-title":"BMC Neurol"},{"issue":"Pt 11","key":"703_CR71","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1093\/brain\/awn234","volume":"131","author":"DS Knopman","year":"2008","unstructured":"Knopman DS, Kramer JH, Boeve BF, Caselli RJ, Graff-Radford NR, Mendez MF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. 2008;131(Pt 11):2957\u201368.","journal-title":"Brain."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00703-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-020-00703-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00703-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T09:35:13Z","timestamp":1618133713000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00703-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00703-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"24 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Goldman\u2014Dr. Goldman has received grant\/research funding from Michael J. Fox Foundation and Parkinson\u2019s Foundation, served as consultant for Worldwide Med, and has received honoraria from Davis Phinney Foundation, International Parkinson and Movement Disorder Society, and Parkinson\u2019s Foundation.Forsberg\u2014Dr. Forsberg has nothing to disclose.Boeve\u2014Dr. Boeve has received grant\/research funding from the NIH (AG016574, AG062677, NS100620, AG056639, AG054256, AG050326), the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, and the Little Family Foundation and serves as an investigator for clinical trials sponsored by Biogen, Alector, and EIP Pharma; Scientific Advisory Board of the Tau Consortium.Armstrong\u2014Dr. Armstrong has received grant\/research funding from AHRQ (K08HS24159), NIA P30AG047266, and the Florida Department of Health (grant 20A08) and compensation from the AAN for work as an evidence-based medicine methodology consultant and is on the level of evidence editorial board for Neurology\u00ae and related publications (uncompensated).Irwin\u2014Dr. Irwin has received grant\/research funding from NIH NS109260, U01-NS100610, R01-AG056014, P30-AG010124, U19-AG062418, and Penn Institute on Aging.Ferman\u2014Dr. Ferman has nothing to disclose.Galasko\u2014Dr. Galasko has received grant\/research funding from NIH\/NIA, State of California, and Michael J Fox Foundation and serves as a consultant to Esai, Biogen, Fujirebio, Amprion, vTv Pharmaceuticals, and DSMB for Cognition Therapeutics.Galvin\u2014Dr. Galvin is the creator of the Lewy Body Composite Risk Score.Kaufer\u2014Dr. Kaufer has nothing to report.Leverenz\u2014Dr. Leverenz has received grant\/research funding from NIH\/NINDS and GE Healthcare and has received consultant fees from Acadia, Eisai, and Sunovion.Lippa\u2014Dr. Lippa has received clinical trial research support from Acadia and Axovant.Marder\u2014Dr. Marder has received grant\/research funding from NIH (U01NS100600, U24NA107168, UL1TR001873, R01NS0736 71, R01LM00986, R01NS-9435, RM1HG007257), Michael J. Fox Foundation, Parkinson\u2019s Foundation, CHDI, and Huntington's Disease Society of America.Abler\u2014Dr. Abler is a full-time employee of Acadia Pharmaceuticals.Biglan\u2014Dr. Biglan is a full-time employee and has a minor shareholder stake in Eli Lilly and Company.Irizarry\u2014Dr. Irizarray is a full-time employee of Eisai, Inc.Keller\u2014Mr. Keller is a full-time employee of Acadia Pharmaceuticals.Munsie\u2014Ms. Munsie is a full-time employee and has a minor shareholder stake in Eli Lilly and Company.Nakagawa\u2014Mr. Nakagawa is a full-time employee of Eisai Co., Ltd.Taylor\u2014Ms. Taylor is a full-time employee and Senior Director of Research and Advocacy for the Lewy Body Dementia Association.Graham\u2014Mr. Graham is the Executive Director of the Lewy Body Dementia Association.Drs. Goldman, Boeve, Armstrong, Irwin, Galasko, Galvin, Kaufer, Leverenz, Lippa, and Marder have received grant funding from the Lewy Body Dementia Association Research Center of Excellence program.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}